Skip to content

Advertisement

Annals of General Psychiatry

Open Access

The use of amisulpride in schizophrenic patients with resistant symptomatology

  • Dimitrios Kalfas1,
  • Sophia Markou1,
  • Apostolos Gkletsos1,
  • Maria Parga1 and
  • Theodoros Karras1
Annals of General Psychiatry20109(Suppl 1):S135

https://doi.org/10.1186/1744-859X-9-S1-S135

Published: 22 April 2010

Background

The purpose of this study was to evaluate the use of the pharmaceutical drug Amisulpride (Solian) in schizophrenic patients with resistant semiology

Materials and methods

The material of this study was 21 patients (17 men and 4 women) who were diagnosed with schizophrenic disorder paranoid type based on DSM-IV, and were recorded with durable symptomatology (delusions, paranoid ideas etc.) even though the continuous issuing of Amisulpride in normal doses (800-1200 mg/daily). In these patients was given Amisulpride in larger doses than the proposed (1600-2000 mg/daily). The evaluation was done with the PANSS scale

Results

After a 30 day time interval and while the continuous issuing of Amisulpride in larger doses was observed considerably reprocess of the resistant symptoms, fact that recorded at the grade alleviation at PANSS scale

Conclusions

Is concluding that the continuous issuing of Amisulpride in larger doses than the normal ones help considerably in obliteration of the durable symptoms of schizophrenia.

Authors’ Affiliations

(1)
Psychiatric Clinic, Giannitsa General Hospital, Greece

Copyright

© Kalfas et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.

Advertisement